Proteomics International Laboratories Ltd (PIQ) - Net Assets
Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has net assets worth AU$12.97 Million AUD (≈ $9.18 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$14.78 Million ≈ $10.46 Million USD) and total liabilities (AU$1.81 Million ≈ $1.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Proteomics International Laboratories Lt asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$12.97 Million |
| % of Total Assets | 87.73% |
| Annual Growth Rate | 9.17% |
| 5-Year Change | 70.41% |
| 10-Year Change | 1538.5% |
| Growth Volatility | 82.21 |
Proteomics International Laboratories Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Proteomics International Laboratories Lt for the complete picture of this company's asset base.
Annual Net Assets for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual net assets of Proteomics International Laboratories Ltd from 2014 to 2025. For live valuation and market cap data, see Proteomics International Laboratories Lt market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$12.97 Million ≈ $9.18 Million |
+40.20% |
| 2024-06-30 | AU$9.25 Million ≈ $6.54 Million |
+11.12% |
| 2023-06-30 | AU$8.32 Million ≈ $5.89 Million |
+145.25% |
| 2022-06-30 | AU$3.39 Million ≈ $2.40 Million |
-55.40% |
| 2021-06-30 | AU$7.61 Million ≈ $5.38 Million |
+71.46% |
| 2020-06-30 | AU$4.44 Million ≈ $3.14 Million |
+48.61% |
| 2019-06-30 | AU$2.99 Million ≈ $2.11 Million |
-36.14% |
| 2018-06-30 | AU$4.68 Million ≈ $3.31 Million |
+190.48% |
| 2017-06-30 | AU$1.61 Million ≈ $1.14 Million |
+103.42% |
| 2016-06-30 | AU$791.42K ≈ $559.98K |
-56.16% |
| 2015-06-30 | AU$1.81 Million ≈ $1.28 Million |
-63.46% |
| 2014-06-30 | AU$4.94 Million ≈ $3.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Proteomics International Laboratories Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3634305300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$47.64 Million | 361.70% |
| Other Comprehensive Income | AU$3.32 Million | 25.20% |
| Total Equity | AU$13.17 Million | 100.00% |
Proteomics International Laboratories Ltd Competitors by Market Cap
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Richmond Vanadium Technology Ltd
AU:RVT
|
$28.06 Million |
|
Agroton Public Ltd.
WAR:AGT
|
$28.06 Million |
|
Perdana Gapura Prima Tbk
JK:GPRA
|
$28.07 Million |
|
Proximar Seafood AS
OL:PROXI
|
$28.09 Million |
|
Imugene Ltd
AU:IMU
|
$28.04 Million |
|
Old Market Capital Corporation
NASDAQ:OMCC
|
$28.03 Million |
|
Evaxion Biotech AS
NASDAQ:EVAX
|
$28.02 Million |
|
Fathom Holdings Inc
NASDAQ:FTHM
|
$28.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Proteomics International Laboratories Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,412,518 to 13,170,446, a change of 3,757,928 (39.9%).
- Net loss of 8,114,797 reduced equity.
- Share repurchases of 11,203,130 reduced equity.
- New share issuances of 11,203,125 increased equity.
- Other comprehensive income increased equity by 1,045,347.
- Other factors increased equity by 10,827,383.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-8.11 Million | -61.61% |
| Share Repurchases | AU$11.20 Million | -85.06% |
| Share Issuances | AU$11.20 Million | +85.06% |
| Other Comprehensive Income | AU$1.05 Million | +7.94% |
| Other Changes | AU$10.83 Million | +82.21% |
| Total Change | AU$- | 39.92% |
Book Value vs Market Value Analysis
This analysis compares Proteomics International Laboratories Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.73x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.88x to 2.73x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-06-30 | AU$0.27 | AU$0.24 | x |
| 2015-06-30 | AU$0.07 | AU$0.24 | x |
| 2016-06-30 | AU$0.02 | AU$0.24 | x |
| 2017-06-30 | AU$0.03 | AU$0.24 | x |
| 2018-06-30 | AU$0.08 | AU$0.24 | x |
| 2019-06-30 | AU$0.04 | AU$0.24 | x |
| 2020-06-30 | AU$0.05 | AU$0.24 | x |
| 2021-06-30 | AU$0.07 | AU$0.24 | x |
| 2022-06-30 | AU$0.03 | AU$0.24 | x |
| 2023-06-30 | AU$0.07 | AU$0.24 | x |
| 2024-06-30 | AU$0.07 | AU$0.24 | x |
| 2025-06-30 | AU$0.09 | AU$0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Proteomics International Laboratories Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -844.95%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.12x
- Recent ROE (-61.61%) is above the historical average (-68.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -4.99% | -21.85% | 0.22x | 1.06x | AU$-740.60K |
| 2015 | -63.66% | -188.89% | 0.24x | 1.40x | AU$-1.33 Million |
| 2016 | -167.86% | -162.63% | 0.50x | 2.05x | AU$-1.41 Million |
| 2017 | -56.93% | -99.04% | 0.32x | 1.79x | AU$-1.08 Million |
| 2018 | -30.80% | -122.41% | 0.21x | 1.17x | AU$-1.91 Million |
| 2019 | -69.66% | -141.70% | 0.41x | 1.21x | AU$-2.38 Million |
| 2020 | -39.29% | -122.54% | 0.26x | 1.25x | AU$-2.19 Million |
| 2021 | -37.58% | -218.16% | 0.15x | 1.13x | AU$-3.62 Million |
| 2022 | -146.53% | -333.91% | 0.28x | 1.59x | AU$-5.31 Million |
| 2023 | -74.39% | -853.62% | 0.07x | 1.20x | AU$-7.07 Million |
| 2024 | -67.74% | -714.71% | 0.08x | 1.16x | AU$-7.32 Million |
| 2025 | -61.61% | -844.95% | 0.06x | 1.12x | AU$-9.43 Million |
Industry Comparison
This section compares Proteomics International Laboratories Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,810,720
- Average return on equity (ROE) among peers: -71.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Proteomics International Laboratories Ltd (PIQ) | AU$12.97 Million | -4.99% | 0.14x | $28.05 Million |
| Adalta Ltd (1AD) | $3.70 Million | -162.25% | 0.87x | $6.50 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $-1.33 Million | 0.00% | 0.00x | $20.04 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $3.20 Million |
| Actinogen Medical Ltd (ACW) | $21.74 Million | -43.69% | 0.07x | $105.70 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $15.45 Million |
| Arovella Therapeutics Ltd (ALA) | $11.03 Million | -40.87% | 0.23x | $58.08 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $20.73 Million | -6.40% | 0.01x | $76.95 Million |
| Amplia Therapeutics Ltd (ATX) | $11.23 Million | -30.16% | 0.02x | $50.82 Million |
| Avecho Biotechnology Ltd (AVE) | $3.27 Million | -95.48% | 0.53x | $28.59 Million |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more